Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

NCT00069706 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: AL-12182 0.003% Ophthalmic Solution
OTHER: AL-12182 Ophthalmic Solution Vehicle
DRUG: Latanoprost 0.005% Ophthalmic Solution
DRUG: AL-12182 0.01% Ophthalmic Solution
DRUG: AL-12182 0.03% Ophthalmic Solution

Sponsor

Alcon Research